Based on previous studies, DDX4 has already been recognized as a potential molecular target for chemotherapy due to its involvement in regulating cell cycle progression in various somatic-derived blood cancer cells [34]. Here, DDX4 is linked to hematopoietic and lymphoid system neoplasm.